This clinical trial is focused on studying the effects of a medication called Ocrevus on patients with multiple sclerosis (MS), a disease that affects the brain and spinal cord, leading to symptoms like fatigue, difficulty walking, and vision problems. The study is comparing two different treatment schedules: one group will receive Ocrevus infusions once a year, while the other group will receive them twice a year. The purpose of the study is to see if the less frequent treatment is as effective as the more frequent one in preventing new disease activity as seen on MRI scans, which are imaging tests that help doctors see inside the body.

Participants in the study will have already been treated with Ocrevus for at least two years. The study will last for two more years, during which time participants will continue to receive their assigned treatment schedule. Throughout the study, participants will undergo regular MRI scans to check for any new signs of disease activity. The study will also monitor for any relapses, which are periods when symptoms get worse, and any changes in disability levels, which refer to how much the disease affects daily activities.

In addition to monitoring disease activity, the study will also look at other health factors, such as changes in certain blood proteins and the occurrence of infections or other health issues. This information will help researchers understand the overall impact of the different treatment schedules on patients’ health and well-being. The study aims to provide valuable insights into the best way to manage multiple sclerosis with Ocrevus treatment.